{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:41Z","timestamp":1793040881322,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n Canaria de Investigacion y Salud","award":["08\/115"],"award-info":[{"award-number":["08\/115"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.pnpbp.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T22:30:52Z","timestamp":1486506652000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Day\/night changes in serum S100B protein concentrations in acute paranoid schizophrenia"],"prefix":"10.1016","volume":"75","author":[{"given":"Armando L.","family":"Morera-Fumero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"D\u00edaz-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Abreu-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Fernandez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Rosario","family":"Cejas-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.02.007_bb0005","doi-asserted-by":"crossref","first-page":"e106342","DOI":"10.1371\/journal.pone.0106342","article-title":"Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia","volume":"9","author":"Aleksovska","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0924-977X(03)00016-6","article-title":"S100B and response to treatment in major depression: a pilot study","volume":"13","author":"Arolt","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1373\/49.5.836","article-title":"Reference values for serum S-100B protein depend on the race of individuals","volume":"49","author":"Ben-Abdesselam","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.psychres.2016.09.029","article-title":"Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia","volume":"247","author":"Chen","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1192\/bjp.153.4.564","article-title":"The viral theory of schizophrenia","volume":"153","author":"Crow","year":"1988","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/sbn187","article-title":"The neurodevelopmental hypothesis of schizophrenia, revisited","volume":"35","author":"Fatemi","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-9964(99)00146-2","article-title":"Decreased S100-beta protein in schizophrenia: preliminary evidence","volume":"43","author":"Gattaz","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1515\/CCLM.2010.262","article-title":"S100B protein increases in human blood and urine during stressful activity","volume":"48","author":"Gazzolo","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0050","first-page":"323","article-title":"Negative correlation between serum S100B and Leptin levels in schizophrenic patients during treatment with clozapine and risperidone: preliminary evidence","volume":"15","author":"Hendouei","year":"2016","journal-title":"Iran J. Pharm. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0055","doi-asserted-by":"crossref","first-page":"27584","DOI":"10.1038\/srep27584","article-title":"Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers","volume":"6","author":"Hong","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0060","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0070","first-page":"395","article-title":"Analysis of reference values of serum S100B concentrations of Japanese adults","volume":"53","author":"Ikeda","year":"2005","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/138955711795906941","article-title":"Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?","volume":"11","author":"Kato","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/074873002129002474","article-title":"Comparisons of the variability of three markers of the human circadian pacemaker","volume":"17","author":"Klerman","year":"2002","journal-title":"J. Biol. Rhythm."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-7-31","article-title":"Acetylsalicylic acid as an adjuvant therapy for schizophrenia","volume":"7","author":"Laan","year":"2006","journal-title":"Trials"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-3956(01)00003-6","article-title":"Increased serum S100B protein in schizophrenia: a study in medication-free patients","volume":"35","author":"Lara","year":"2001","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jpsychires.2005.11.006","article-title":"Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment","volume":"41","author":"Ling","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fncel.2016.00033","article-title":"Serum S100B protein is specifically related to white matter changes in schizophrenia","volume":"10","author":"Milleit","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pnpbp.2011.12.002","article-title":"Neuroinflammation in schizophrenia especially focused on the role of microglia","volume":"42","author":"Monji","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2007.00467.x","article-title":"Daytime\/night-time and summer\/winter melatonin and malondialdehyde rhythms: an inverse relationship","volume":"43","author":"Morera","year":"2007","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/15622970801901802","article-title":"Winter\/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research","volume":"10","author":"Morera","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0130","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.3390\/ijms14059037","article-title":"Role of melatonin in schizophrenia","volume":"14","author":"Morera-Fumero","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0135","first-page":"253","article-title":"Relationships between stress factors, depression and medical illness","volume":"4","author":"Morera-Fumero","year":"1983","journal-title":"Psiquis"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jpsychires.2013.03.001","article-title":"Summer\/winter changes in serum S100B protein concentration as a source of research variance","volume":"47","author":"Morera-Fumero","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"Muller","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0150","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.pnpbp.2008.07.017","article-title":"Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia","volume":"32","author":"Pedersen","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neulet.2009.06.019","article-title":"Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics","volume":"462","author":"Qi","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.mp.4000889","article-title":"Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology","volume":"6","author":"Rothermundt","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0165","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.npp.1300403","article-title":"S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia","volume":"29","author":"Rothermundt","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0170","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.mp.4001548","article-title":"Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF","volume":"9","author":"Rothermundt","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.pnpbp.2006.09.013","article-title":"Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol","volume":"31","author":"Rothermundt","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.pnpbp.2007.03.008","article-title":"Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment","volume":"31","author":"Sarandol","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.schres.2005.04.013","article-title":"Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms","volume":"80","author":"Schmitt","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(02)00383-3","article-title":"Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia","volume":"62","author":"Schroeter","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.psychres.2008.01.002","article-title":"Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia\u2013original research and meta-analysis","volume":"167","author":"Schroeter","year":"2009","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fncel.2016.00046","article-title":"Serum S100B is related to illness duration and clinical symptoms in schizophrenia-A meta-regression analysis","volume":"10","author":"Schumberg","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0205","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/jnr.21211","article-title":"S100B in neuropathologic states: the CRP of the brain?","volume":"85","author":"Sen","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0210","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/jnnp.2006.093427","article-title":"Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones","volume":"77","author":"Steiner","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0215","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.biopsych.2008.10.044","article-title":"A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE","volume":"65","author":"Steiner","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0220","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00415-009-0124-y","article-title":"Serum S-100B protein levels in patients with herpes simplex encephalitis and tick-borne encephalitis \u2013 a marker of CNS damage during the initial stage of disease","volume":"256","author":"Studahl","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0225","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9120(03)00107-3","article-title":"Influence of anticoagulants on the measurement of S100B protein in blood","volume":"36","author":"Tort","year":"2003","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0230","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jpsychires.2013.04.004","article-title":"Increased plasma agmatine levels in patients with schizophrenia","volume":"47","author":"Uzbay","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0235","series-title":"The Handbook of Neurosychiatric Biomarkers, Endophenotypes and Genes","first-page":"13","article-title":"S100B as a potential neurochemical biomarker in a variety of neurological, neuropsychiatric and neurosurgical disorders","author":"Wainwright","year":"2009"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0240","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0006-3223(98)00217-0","article-title":"Elevated plasma levels of S-100b protein in schizophrenic patients","volume":"45","author":"Wiesmann","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0245","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/pcn.12024","article-title":"S100B and schizophrenia","volume":"67","author":"Yelmo-Cruz","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0255","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jpsychires.2010.04.023","article-title":"Increased serum S100B in never-medicated and medicated schizophrenic patients","volume":"44","author":"Zhang","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2017.02.007_bb0260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jpsychires.2009.10.012","article-title":"Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements","volume":"44","author":"Zhang","year":"2010","journal-title":"J. Psychiatr. Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616304407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616304407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T05:10:17Z","timestamp":1529644217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584616304407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"alternative-id":["S0278584616304407"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.02.007","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Day\/night changes in serum S100B protein concentrations in acute paranoid schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}